French Gene Therapy Biotech Gets Ready for Phase II/III – Labiotech.eu (blog)
|
French Gene Therapy Biotech Gets Ready for Phase II/III
Labiotech.eu (blog) Lysogene has crunched the numbers on its observational study for Sanfillipo A – now the company can move into the final phase for its Sanfilippo A therapy. Lysogene is a French biotech specializing in gene therapy of rare CNS diseases. Its lead asset … |
